Prescient Therapeutics Limited (ASX:PTX – Get Free Report) insider Gavin Shepherd acquired 614,092 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was purchased at an average price of A$0.04 ($0.03) per share, with a total value of A$26,405.96 ($16,819.08).
Prescient Therapeutics Price Performance
The stock has a market capitalization of $38.66 million, a price-to-earnings ratio of -4.69 and a beta of 1.19. The company has a debt-to-equity ratio of 1.83, a quick ratio of 17.31 and a current ratio of 8.08.
Prescient Therapeutics Company Profile
See Also
- Five stocks we like better than Prescient Therapeutics
- Investing in the High PE Growth Stocks
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Must-Own Stocks to Build Wealth This Decade
- What is the FTSE 100 index?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Prescient Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prescient Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.